ArticleScientific reports2025
Integrated experimental and computational analysis reveals amoxicillin binding dynamics to PBP1a in Staphylococcus aureus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Novel Nanoantibiotic Formulation With Magnetic and Targeting Potential: Ampicillin-Conjugated L-glu-FeMicrobiologyOpen · 2026Article
- Pharmacokinetics, molecular docking, and molecular dynamics simulation unveil novel lichen-derived scaffolds targeting PBP2a MRSA.Frontiers in bioinformatics · 2026Article
- Integrated experimental and computational study reveals enhanced antimicrobial efficacy of amoxicillin loaded in oleic acid nanoemulsion against multidrug-resistantRSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) represents a significant global health challenge due to acquired resistance mechanisms, primarily involving penicillin-binding protein 2a (PBP2a), necessitating novel therapeutic strategies. This study explores the potential of amoxicillin-conjugated magnetic nanoparticles (Amox-MNPs) as a means to overcome resistance by targeting the alternative essential protein, PBP1a. Fe₃O₄@SiO₂ core-shell MNPs were synthesized via controlled co-precipitation followed by a silica coating using the Stöber method, and subsequently conjugated with amoxicillin. Physicochemical characterization confirmed nanoparticle formation and successful conjugation. In vitro antibacterial assays against S. aureus ATCC 43,300 (MRSA) revealed that Amox-MNPs exhibited a mean inhibition zone diameter of 26.0 ± 0.82 mm, approximately double that of free amoxicillin (13.5 ± 1.12 mm) at equivalent concentrations (p < 0.05), indicating significantly enhanced antibacterial efficacy. Integrated computational modeling, including molecular docking and dynamics simulations, elucidated the favorable binding (-8.64 kcal/mol docking score;-32.65 kcal/mol MM-PBSA energy) and stable interaction dynamics between amoxicillin and PBP1a, identifying key stabilizing residues. These findings highlight the potential of MNP-mediated delivery to enhance amoxicillin's efficacy against MRSA by targeting PBP1a, offering a promising preclinical strategy requiring further validation in animal models for combating resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.